By Staff
Friday, January 24, 2020 12:18 AM
SAN RAMON, Calif.—A study commissioned by
CooperVision among new contact lenses wearers offers valuable information that ECPs can use to reach new patients and reduce dropout.
By Staff
Thursday, January 23, 2020 12:21 AM
NEW BRUNSWICK, N.J.—
Johnson & Johnson (NYSE: JNJ) reported Wednesday that its sales rose in the low single digits in both the fourth quarter and full year 2019 as all three of its business segments achieved growth. The U.S. segment of the company’s contact lens business—a small piece of the company’s overall business—achieved mid-single digit growth in both the fourth quarter and full year, driven in part by the results of the Acuvue contact lens franchise, according to the announcement.
By Staff
Wednesday, January 22, 2020 12:21 AM
SAN RAMON, Calif.—CooperVision has named Jane Agbontaen as senior brand director for myopia management–Americas, according to an announcement this week. In this newly created role, Agbontaen will be responsible for the strategic planning and execution of all activities that support the U.S. growth of CooperVision’s myopia management portfolio—specifically the Brilliant Futures Myopia Management Program with MiSight 1 day, the first and only FDA-approved product clinically proven to slow the progression of myopia when initially prescribed for children 8-12 years old in the U.S.
By Staff
Friday, January 17, 2020 12:27 AM
ALEXANDRIA, Va.—
The Vision Council announced Thursday that the U.S. and China have signed a phase one trade deal that requires structural reforms to China’s economic and trade regimes. The agreement also will lead to a modification of a portion of the existing Section 301 China tariffs. This modification is “a point of interest” to association members who import Chinese-origin product, The Vision Council noted. The overall reforms will be seen in the areas of intellectual property, forced technology transfers, financial services, agriculture, and currency and financial exchanges. In addition, China has agreed to purchase substantial quantities of U.S. origin goods and services in the coming years.
By Staff
Friday, January 17, 2020 12:18 AM
DUBLIN—
Allergan plc (NYSE: AGN), a global pharmaceutical company with more than 70 years of heritage in eyecare, announced a partnership with Von Miller, a former Super Bowl MVP, Denver Broncos linebacker and advocate for healthy vision, to shine a light on the millions of people living with glaucoma. As an ambassador for the
“My Glaucoma” campaign, Miller will address the misunderstandings and impact of glaucoma and encourage those with the disease, and their caregivers, to take early action, according to the announcement this week. This includes going to the doctor regularly and taking medications as prescribed.
By Staff
Thursday, January 16, 2020 12:21 AM
SAN RAMON, Calif.—
CooperVision, which is preparing for the March 2020 U.S. launch of
MiSight 1 day contact lenses, has kicked off the new year by announcing this week the details of its comprehensive myopia management approach. An initial group of eyecare professionals (ECPs) gathered in Miami on Jan. 7-8 to learn about the “Brilliant Futures Myopia Management Program” and to prepare to prescribe the MiSight 1 day lens to patients. CooperVision’s MiSight 1 day lens is the first and only product approved by the Food and Drug Administration for slowing the progression of myopia when initially prescribed for children 8-12 years old, as
VMAIL reported.
By Staff
Tuesday, January 14, 2020 12:15 AM
CAMBRIDGE, England—
Exonate, an early stage biotechnology company based here, said Monday that it has entered into a strategic collaboration agreement with
Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, that will work toward developing an eye drop treatment for retinal vascular diseases, such as Age-Related Macular Degeneration (AMD) and Diabetic Macular Oedema (DMO). The effort will focus on using mRNA targeted therapies. The agreement was facilitated by Johnson & Johnson Innovation. Exonate has developed small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing, according to the announcement.
By Staff
Wednesday, January 8, 2020 12:24 AM
ORLANDO, Fla.—
Essilor of America is kicking off 2020, “The Year of Vision,” by launching an array of new programs and products designed to strengthen the company’s relationships with independent eyecare professionals by expanding its premium spectacle lens lines and introducing digital technologies that enhance the patient experience.
By Staff
Wednesday, January 8, 2020 12:15 AM
PLEASANTON, Calif.—
Samsung Electronics Co. and
IrisVision, a leader in digital vision technologies and maker of the world's first smart, wearable vision-assistive device, announced a strategic partnership to roll out IrisVision's groundbreaking technology worldwide. IrisVision's vision correction software platform utilizes the power of Samsung's industry leading Galaxy smartphones and XR devices and mobile AI platform to enable people with impaired vision to see clearly and live more independent lives, according to the announcement on Tuesday.
By Staff
Friday, December 27, 2019 12:21 AM
CHICAGO—According to estimates from the
Prevent Blindness report, “Future of Vision: Forecasting the Prevalence and Costs of Vision Problems,” more than 3.2 million Americans ages 40 and over have glaucoma in the year 2020. The number is expected to increase as the population ages. Glaucoma, often referred to as the "The Sneak Thief of Sight," is a leading cause of vision loss that damages the optic nerve. Although symptoms may not be noticeable at first, glaucoma slowly diminishes peripheral vision (side vision), making activities such as driving increasingly, according to a Prevent Blindness announcement this week.
By Staff
Thursday, December 26, 2019 12:24 AM
LAVAL, Quebec, and HEIDELBERG, Germany—
Bausch Health Companies Inc. (NYSE/TSX: BHC) and
Bausch + Lomb, its leading global eye health business, and
Novaliq GmbH, a pharmaceutical company focused on ocular therapeutics, announced late last week a licensing agreement for an investigational dry eye treatment. Bausch Health has acquired an exclusive license for the sale and development in the U.S. and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat dry eye disease (DED) associated with Meibomian gland dysfunction (MGD), according to the joint announcement.
By Staff
Monday, December 23, 2019 12:15 AM
RANCHO CORDOVA, Calif.—The
VSP Global Premier Program has announced a partnership with
Tura, Inc.
By Staff
Friday, December 20, 2019 12:18 AM
CORAL SPRINGS, Fla.—
ABB Optical Group chief executive officer Tom Burke has been named one of the South Florida Business Journal’s 2019 Power Leaders in Health Care. The annual list honors 50 South Florida-based health care industry leaders who drive innovation and award-winning patient care, according to an ABB Optical announcement. A health care logistics leader with nearly 40 years of experience, Burke has guided world-class organizations through extraordinary growth trajectories, the announcement noted. During his time at ABB Optical Group, he has helped expand the company’s operations and solidified its role as a leading national provider of optical products and business solutions for the eyecare industry, the announcement noted. Most recently, he has led the rebranding of ABB Optical Group, refreshing the company’s brand identity and reinforcing its commitment to eyecare professionals.